Title:
PEPTIDE THIOUREA DERIVATIVE, RADIOISOTOPE LABELED COMPOUND CONTAINING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING OR DIAGNOSING PROSTATE CANCER
Document Type and Number:
WIPO Patent Application WO/2017/082620
Kind Code:
A1
Abstract:
The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound containing the same, and a pharmaceutical composition containing the same as an active ingredient for treating and diagnosing prostate cancer. The peptide thiourea derivative according to the present invention, when administered into the body, has excellent stability in the human serum, favorably binds to PSMA which is competitively expressed in prostate cancer, exhibits an excellent PSMA inhibitory effect with a low concentration, and can obtain a clear image of a prostate cancer tumor site by being excreted into the kidney rather than the hepatobiliary route due to high water solubility thereof. Therefore, the peptide thiourea derivative according to the present invention can be favorably used as a pharmaceutical composition for treating or diagnosing prostate cancer.
More Like This:
Inventors:
JEONG JAE MIN (KR)
MOON SUNG-HYUN (KR)
LEE YUN-SANG (KR)
MOON SUNG-HYUN (KR)
LEE YUN-SANG (KR)
Application Number:
PCT/KR2016/012849
Publication Date:
May 18, 2017
Filing Date:
November 09, 2016
Export Citation:
Assignee:
CELLBION CO LTD (KR)
International Classes:
C07K5/02; A61K31/41; A61K51/06; A61K51/08; C07D257/02; C07K5/072; G01N33/574; G01N33/60
Foreign References:
| US8926944B2 | 2015-01-06 | |||
| KR20040044562A | 2004-05-31 | |||
| KR20120048250A | 2012-05-15 | |||
| KR20150104092A | 2015-09-14 | |||
| JP2015089881A | 2015-05-11 |
Other References:
See also references of EP 3375787A4
Attorney, Agent or Firm:
LEE, Won Hee (KR)
Download PDF: